3 results about "STAT5" patented technology

The application discloses application of SGI-7079 in treating FLT3 mutant acute myeloid leukemia. The application research shows that SGI-7079 can be stably combined with FLT3, inhibit the phosphorylation level of FLT3 and downstream STAT5, AKT and ERK, and induce G1 phase arrest and cell apoptosis. In vitro, SGI-7079 has strong inhibitory effect on FLT3-ITD and drug-resistant mutant cells; in a FLT3-ITD mouse model, SGI-7079 can significantly reduce leukemia load and prolong survival, and shows better curative effect than existing drugs on drug-resistant mutations such as F691L and D835Y. Meanwhile, SGI-7079 also has significant inhibitory effect on primary cells of FLT3-ITD positive patients. It is shown that SGI-7079 can be used as a new drug candidate for treating FLT3 mutation and drug-resistant AML, and provides a new direction for optimizing targeted therapy strategy.

In one embodiment, a problem to be solved by the present invention is to provide a new agent the agent being for at least one selected from the group consisting of promoting breast milk secretion, enhancing breast milk secretion function, improving inhibition of breast milk secretion function, and inhibiting mammary gland involution, said agent comprising, as an active ingredient, a substance that has not heretofore been known to have a breast milk secretion promoting effect. The present invention provides an agent for at least one selected from the group consisting of promoting breast milk secretion, enhancing breast milk secretion function, improving inhibition of breast milk secretion function, and inhibiting mammary gland involution, said agent containing a starting material derived from at least one selected from the group consisting of oranges, aloe, carrots, American ginseng, figs, almonds, hyuganatsu, laurel, apples, soybeans, chrysanthemums, wheatgrass, pepper, ginger, ebi-imo, Japanese yams, kuugaimo, Nikko maple, poppies, and radishes.

The application provides a preparation method of paeonol glycoside for inhibiting GM-CSF + The application belongs to the technical field of biological medicine, and relates to application of Th cell differentiation in a medicine for preventing and / or treating rheumatoid arthritis (RA). + Abnormal activation of Th cells is obviously earlier than appearance of clinical symptoms of RA in a time axis, is an early key initiating factor for driving occurrence of the RA disease, and is a core target point for implementing an early blocking strategy. + Further, it is found that paeonol glycoside (Alb) can block a gamma c / JAK3 / STAT5 signal path by targeting and combining with an interleukin-2 receptor gamma chain, down-regulate CSF2 gene transcription and GM-CSF protein expression, thereby inhibiting differentiation of Th cells, and finally achieving an effect of preventing occurrence of CIA arthritis and not rebounding after drug withdrawal. The application provides a new intervention medicine which is high in safety, suitable for long-term use, can effectively regulate immune abnormalities in a pre-RA stage, prevents rheumatoid arthritis, and has a wide application prospect.